Skip to main content
SpringerLink
Log in

Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Among other phenotypic markers, CD11b expression has been considered as an unfavorable prognostic factor, both in terms of overall survival (OS), disease-free survival (DFS), and attainment and duration of complete remissions (CRs) in adult patients with acute myeloid leukemia (AML). Recently, some groups have restricted its prognostic impact to poor prognostic karyotypic risk groups. The aim of this study was to retrospectively analyze the prevalence of CD11b and of CD56 expression in blast cells of 158 AML patients [excluding those with t(15;17)] stratified according to their cytogenetic risk and to correlate these phenotypic characteristics with OS, DFS, and CR. CD11b was more frequently expressed in intermediate and unfavorable cytogenetic prognostic groups (38.9 and 35.5 %, respectively) than in the favorable group (9.5 %). No differences were observed in CD56 expression according to the cytogenetic risk groups. When OS, DFS, and CR were analyzed according to these two markers, no statistical differences were recorded in any cytogenetic risk group. In conclusion, although CD11b was more frequently expressed in blast cells of patients with intermediate and unfavorable cytogenetic risk groups, this feature did not translate into different clinical outcome. Similarly, CD56 positivity did not have any influence on the prognosis of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mason KD, Juneja SK, Szer J (2006) The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? Blood Rev 20:71–82

    Article  CAS  PubMed  Google Scholar 

  2. Ossenkoppele GJ, van de Loosdrecht AA, Schuurhuis GJ (2011) Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol 153:421–436

    Article  CAS  PubMed  Google Scholar 

  3. Yang DH, Lee JJ, Mun YC, Shin HJ, Kim YK, Cho SH et al (2007) Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. Am J Hematol 82:1–5

    Article  CAS  PubMed  Google Scholar 

  4. Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F et al (2000) CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 18:1295–1300

    CAS  PubMed  Google Scholar 

  5. Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G et al (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 15:1161–1164

    Article  CAS  PubMed  Google Scholar 

  6. Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD (2004) Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 28:43–48

    Article  CAS  PubMed  Google Scholar 

  7. Jiang A, Jiang H, Brandwein J, Kamel-Reid S, Chang H (2011) Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. Leuk Res 35:492–498

    Article  CAS  PubMed  Google Scholar 

  8. Dang H, Jiang A, Kamel-Reid S, Brandwein J, Chang H (2013) Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype. Hum Pathol 44:55–61

    Article  CAS  PubMed  Google Scholar 

  9. Iriyama N, Hatta Y, Takeuchi J, Ogawa Y, Ohtake S, Sakura T et al (2013) CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). Leuk Res 37:1021–1026

    Article  CAS  PubMed  Google Scholar 

  10. Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F (2002) Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica 87:250–256

    PubMed  Google Scholar 

  11. Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G et al (2000) The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 96:870–877

    CAS  PubMed  Google Scholar 

  12. Tucker J, Dorey E, Gregory WM, Simpson AP, Amess JA, Lister TA et al (1990) Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome. Hematol Oncol 8:47–58

    Article  CAS  PubMed  Google Scholar 

  13. Bradstock K, Matthews J, Benson E, Page F, Bishop J (1994) Prognostic value of immunophenotyping in acute myeloid leukemia. Australian leukaemia study group. Blood 84:1220–1225

    CAS  PubMed  Google Scholar 

  14. Tien HF, Wang CH, Lin MT, Lee FY, Liu MC, Chuang SM et al (1995) Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 84:60–68

    Article  CAS  PubMed  Google Scholar 

  15. Paietta E, Andersen J, Yunis J, Rowe JM, Cassileth PA, Tallman MS et al (1998) Acute myeloid leukaemia expressing the leucocyte integrin CD11b-a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. eastern cooperative oncology group. Br J Haematol 100:265–272

    Article  CAS  PubMed  Google Scholar 

  16. Graf M, Reif S, Kroll T, Hecht K, Nuessler V, Schmetzer H (2006) Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis. Am J Hematol 81:227–235

    Article  CAS  PubMed  Google Scholar 

  17. Chen MH, Atenafu E, Craddock KJ, Brandwein J, Chang H (2013) CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavorable acute myeloid leukemia. Leuk Res 37:122–128

    Article  CAS  PubMed  Google Scholar 

  18. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom medical research council trials. Blood 116:354–365

    Article  CAS  PubMed  Google Scholar 

  19. Swerdlow SH, International Agency for Research on Cancer (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer

  20. Nomdedeu J, Bussaglia E, Villamor N, Martinez C, Esteve J, Tormo M et al (2011) Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size. Leuk Res 35:163–168

    Article  CAS  PubMed  Google Scholar 

  21. Shaffer LG, Slovak ML, Campbell LL. ISCN (2009) An international system for human cytogenetic nomenclature. Basel: Karger; 2009

  22. Junca J, Granada I, Rodriguez-Hernandez I, Milla F (2013) CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavourable acute myeloid leukemia. Leuk Res 37:859–860

    Article  CAS  PubMed  Google Scholar 

  23. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J et al (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26:1908–1975

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

All the authors contributed to the writing of this article, and they declare no conflict of interests. JJ analyzed results and wrote the manuscript. IG, MG-C, IR-H, and AT collected data and contributed to the writing of the manuscript. MM was the data manager. JMR contributed to the discussion. FM and EF reviewed the manuscript. All authors approved final manuscript submitted.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Hematology Department, Hospital Germans Trias i Pujol, Institut Català d’Oncologia, Institut de Recerca contra la Leucèmia Josep Carreras, Ctra del Canyet s/n, 08916, Badalona, Catalonia, Spain

    Jordi Juncà, Montse Garcia-Caro, Isabel Granada, Inés Rodríguez-Hernández, Anna Torrent, Mireia Morgades, Josep-Maria Ribera, Fuensanta Millá & Evarist Feliu

Authors
  1. Jordi Juncà
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Montse Garcia-Caro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabel Granada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Inés Rodríguez-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna Torrent
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mireia Morgades
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Josep-Maria Ribera
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fuensanta Millá
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Evarist Feliu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jordi Juncà.

Additional information

Informed consent was obtained from all patients for being included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Juncà, J., Garcia-Caro, M., Granada, I. et al. Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis. Ann Hematol 93, 1483–1489 (2014). https://doi.org/10.1007/s00277-014-2082-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2082-4

Keywords

Search

Navigation